Post-effective Amendment to Registration Statement (pos Am)
16 März 2016 - 3:59PM
Edgar (US Regulatory)
As filed with the Securities and Exchange Commission on March 16,
2016
Registration No. 333-146493
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Post-Effective Amendment No. 1
on
FORM S-1
to
FORM S-3
REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OF 1933
PATHFINDER CELL THERAPY, INC.
(Exact name of registrant as specified in
its charter)
Delaware |
|
3842 |
|
14-1745197 |
(State or other jurisdiction of |
|
(Primary SIC Number) |
|
(I.R.S. Employer |
incorporation or organization) |
|
|
|
Identification No.) |
12 Bow Street
Cambridge, Massachusetts 02138
(617) 245-0289
(Address, including zip code, and telephone
number, including area code, of principal executive offices)
Richard L. Franklin, M.D., Ph.D.
12 Bow Street
Cambridge, Massachusetts 02138
(617) 245-0289
(Name, address, including zip code, and telephone
number, including area code, of agent for service)
With a copy to:
Keith M. Moskowitz, Esq.
Eilenberg & Krause LLP
11 East 44th Street
New York, New York 10017
Tel. (212) 986-9700
Fax (212) 986-2399
If any of the securities being registered
on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the
following box. ¨
If this Form is filed to register additional
securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering. ¨
If this Form is a post-effective amendment
filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement
number of the earlier effective registration statement for the same offering. ¨
If this Form is a post-effective amendment
filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement
number of the earlier effective registration statement for the same offering. ¨
Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions
of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2
of the Exchange Act.
|
|
Large accelerated filer ¨ |
Accelerated filer ¨ |
Non-accelerated filer ¨ (Do not check if a smaller reporting company) |
Smaller reporting company x |
EXPLANATORY NOTE
Pathfinder
Cell Therapy, Inc. (the “Company”) is hereby filing this Post-Effective Amendment No. 1 on Form S-1 to the Company’s
registration statement on Form S-3 (Registration No. 333-146493) (the “Registration Statement”) to remove from registration
all securities of the Company that remain unsold under the Registration Statement.
SIGNATURES
Pursuant to the requirements of the Securities
Act of 1933, as amended, the registrant has duly caused this Post-Effective Amendment on Form S-1 to the Registration Statement
on Form S-3 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of
Massachusetts on March 16, 2016.
|
PATHFINDER CELL THERAPY, INC. |
|
|
|
By: |
/s/
Richard L. Franklin, M.D., Ph.D. |
|
Name: |
Richard L. Franklin, M.D.,
Ph.D.
|
|
Title: |
Chief Executive Officer,
President and Director |
Pursuant to the requirements of the Securities
Act of 1933, this Post-Effective Amendment on Form S-1to the Registration Statement on Form S-3 has been signed by the following
persons in the capacities and on the dates stated.
|
|
|
Signature
|
Title
|
Date
|
/s/ Richard L. Franklin, M.D., Ph.D. |
Chief Executive Officer, President and Director |
|
Richard L. Franklin, M.D., Ph.D. |
(Principal Executive Officer) |
March 16, 2016 |
/s/ John M. Benson |
Chief Financial Officer and Treasurer |
|
John M. Benson |
(Principal Financial and Accounting Officer) |
March 16, 2016 |
/s/ Joerg Gruber |
|
|
Joerg Gruber |
Chairman of the Board of Directors |
March 16, 2016 |
/s/ John L. Brooks III |
|
|
John L. Brooks III |
Director |
March 16, 2016 |
/s/ Zen Chu |
|
|
Zen Chu |
Director |
March 16, 2016 |
/s/ John Alam, M.D. |
|
|
John Alam, M.D. |
Director |
March 16, 2016 |
/s/ Brock Reeve |
|
|
Brock Reeve |
Director |
March 16, 2016 |
Pathfinder Cell Therapy (CE) (USOTC:PFND)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Pathfinder Cell Therapy (CE) (USOTC:PFND)
Historical Stock Chart
Von Jun 2023 bis Jun 2024